Mepolizumab in the treatment of eosinophilic esophagitis

Rana F. Ammoury, Sandeep K. Gupta

Research output: Contribution to journalArticle

1 Scopus citations


Mepolizumab is a humanized monoclonal antibody that binds specifically to and inactivates a protein cell messenger termed IL-5, which plays a major role in the proliferation, maturation, activation and survival of eosinophils. As a result, mepolizumab has been studied in a number of eosinophil-associated diseases, such as asthma, hypereosinophilic syndrome and eosinophilic esophagitis (EE). EE is a clinical entity characterized by eosinophilic infiltration of the esophagus (≥15 eosinophils/high power field in one or more fields) in the absence of gastroesophageal reflux. EE is on the rise, and this can not be fully accounted for by increased recognition. Currently, available therapies, although successful in many cases, can be disappointing in some patients, whether from lack of response, negative impact on quality of life, or significant toxicity. In order to better define EE therapy, investigators are evaluating novel drugs, including anti-IL-5 agents such as mepolizumab. Mepolizumab has been demonstrated to significantly reduce mean blood and tissue eosinophil count. It is well-tolerated and no drug-related serious adverse events have been described in the published literature to date. Mepolizumab is currently under clinical investigation and is not yet available for general use.

Original languageEnglish (US)
Pages (from-to)231-237
Number of pages7
Issue number2
StatePublished - Mar 1 2009


  • Anti-IL-5
  • Eosinophilic esophagitis
  • Mepolizumab

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Fingerprint Dive into the research topics of 'Mepolizumab in the treatment of eosinophilic esophagitis'. Together they form a unique fingerprint.

  • Cite this